. "42944"^^ . "Breast cancer; Lupus; Prostate cancer"^^ . "6-D-Tryptophanluteinizing Hormone-releasing FactorSYNCI" . "triptorelinPTNCI-GLOSSCDR0000045769" . "FDA"^^ . . "C0077275"^^ . . "TRIPTORELINPTFDA9081Y98W2V" . "C1267"^^ . "42944"^^ . . "Triptorelin"^^ . "57773-63-4"^^ . "TriptorelinPTNCI" . "9081Y98W2V"^^ . "Pharmacologic Substance"^^ . "CL-118,532CNNCI" . . . "Triptorelin"^^ . "6-D-Tryptophan-LH-RHSYNCI" . "DetryptorelineSYNCI" . "Amino Acid, Peptide, or Protein"^^ . "AY-25650CNNCI" . . "Triptorelin"^^ . "A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.NCI-GLOSS" . "C64H82N18O13"^^ . "Palliative treatment prostate carcinoma"^^ . "A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)NCI" . "DecapeptylFBNCI" . "CHEBI:63633"^^ .